Compare · EW vs RWLK
EW vs RWLK
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and ReWalk Robotics Ltd. (RWLK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EW and RWLK operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW carries a market cap of $61.59B.
- EW has hit the wire 12 times in the past 4 weeks while RWLK has been quiet.
- EW has more recent analyst coverage (25 ratings vs 0 for RWLK).
- Company
- Edwards Lifesciences Corporation
- ReWalk Robotics Ltd.
- Price
- -
- -
- Market cap
- $61.59B
- -
- 1M return
- +20.55%
- -
- 1Y return
- +24.31%
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 12
- 0
- Recent ratings
- 25
- 0
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
ReWalk Robotics Ltd.
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes wearable robotic exoskeletons for individuals with mobility impairments or other medical conditions in Israel, the United States, Europe, the Asia-Pacific, Latin America, and Africa. It offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for used in the rehabilitation of individuals with lower limb disability due to stroke; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers, institutions, and individuals, as well as through distributors. The company was formerly known as Argo Medical Technologies Ltd. and changed its name to ReWalk Robotics Ltd. ReWalk Robotics Ltd. was founded in 2001 and is headquartered in Yokneam Ilit, Israel.
Latest EW
- SVP, Corporate Controller Dahl Andrew M. covered exercise/tax liability with 101 shares, decreasing direct ownership by 0.69% to 14,606 units (SEC Form 4) to satisfy tax liability
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $64,531 worth of shares (619 units at $104.25) as part of a pre-agreed trading plan (SEC Form 4)
- CEO Zovighian Bernard J exercised 23,100 shares at a strike of $72.68 and sold $2,379,779 worth of shares (23,100 units at $103.02) as part of a pre-agreed trading plan (SEC Form 4)
- CVP,Strategy/Corp Development Bobo Donald E Jr exercised 48,900 shares at a strike of $72.68 and sold $5,039,311 worth of shares (48,900 units at $103.05) as part of a pre-agreed trading plan, decreasing direct ownership by 0.00% to 22,798 units (SEC Form 4)
- Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment
- Edwards Lifesciences upgraded by Robert W. Baird with a new price target
- SEC Form 10-Q filed by Edwards Lifesciences Corporation
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports Third Quarter Results
- Edwards Lifesciences upgraded by Truist with a new price target
Latest RWLK
- VA STAND Act introduced in the United States Senate
- Lifeward Announces Reverse Share Split
- ReStore Exo-Suit Publications Demonstrate Improved Walking Outcomes Versus Conventional Stroke Therapy
- Lifeward announces the Centers for Medicare & Medicaid Services ("CMS") is deferring its final decision on the payment rate for personal exoskeletons so that more recent claims information on the current, more advanced ReWalk Personal Exoskeleton may be considered
- Lifeward Reports Fourth Quarter and Full Year 2023 Financial Results
- Lifeward to Report Fourth Quarter and Fiscal Year-End 2023 Financial Results on February 27, 2024
- ReWalk Robotics Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- ReWalk Robotics Transforms Company Identity, Rebrands as Lifeward
- ReWalk Robotics Expands Direct Sales Coverage to Canada
- ReWalk Robotics Ltd. to Present at Sidoti Virtual Investor Conference on January 17